Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer

Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission... Nucl Med Mol Imaging (2012) 46:207–214 DOI 10.1007/s13139-012-0151-y ORIGINAL ARTICLE Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer Jae Pil Hwang & Ilhan Lim & Kyoung Jin Chang & Byung Il Kim & Chang Woon Choi & Sang Moo Lim Received: 8 March 2012 /Revised: 8 May 2012 /Accepted: 7 June 2012 /Published online: 30 June 2012 Korean Society of Nuclear Medicine 2012 Abstract i.e., there were 1267 days in stage I, 440 days in stage II, Purpose Recent studies have been conducted on the rela- 299 days in stage III, and 143 days in stage IV (p<0.0001). tionship between fluorodeoxyglucose (FDG) uptake in F-18 The median survival was also found to be significantly FDG PET/CT and prognosis in patients with pancreatic related to tumor size (p00.001), site (p00.0298), serum cancer, but these studies have been carried out in small level of CA19-9 (p00.0017), distant metastasis (p< numbers of patients. The aim of this retrospective study 0.0001), and type of treatment (p<0.0001). Multivariate was to determine in a large number of patients whether analysis study revealed that the patients with a low SUV glucose metabolism as assessed by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nuclear Medicine and Molecular Imaging Springer Journals

Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/prognostic-value-of-suvmax-measured-by-fluorine-18-fluorodeoxyglucose-Vg8qpFFRpu

References (44)

Publisher
Springer Journals
Copyright
Copyright © 2012 by Korean Society of Nuclear Medicine
Subject
Medicine & Public Health; Cardiology; Imaging / Radiology; Oncology; Nuclear Medicine; Orthopedics
ISSN
1869-3474
eISSN
1869-3482
DOI
10.1007/s13139-012-0151-y
pmid
24900062
Publisher site
See Article on Publisher Site

Abstract

Nucl Med Mol Imaging (2012) 46:207–214 DOI 10.1007/s13139-012-0151-y ORIGINAL ARTICLE Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer Jae Pil Hwang & Ilhan Lim & Kyoung Jin Chang & Byung Il Kim & Chang Woon Choi & Sang Moo Lim Received: 8 March 2012 /Revised: 8 May 2012 /Accepted: 7 June 2012 /Published online: 30 June 2012 Korean Society of Nuclear Medicine 2012 Abstract i.e., there were 1267 days in stage I, 440 days in stage II, Purpose Recent studies have been conducted on the rela- 299 days in stage III, and 143 days in stage IV (p<0.0001). tionship between fluorodeoxyglucose (FDG) uptake in F-18 The median survival was also found to be significantly FDG PET/CT and prognosis in patients with pancreatic related to tumor size (p00.001), site (p00.0298), serum cancer, but these studies have been carried out in small level of CA19-9 (p00.0017), distant metastasis (p< numbers of patients. The aim of this retrospective study 0.0001), and type of treatment (p<0.0001). Multivariate was to determine in a large number of patients whether analysis study revealed that the patients with a low SUV glucose metabolism as assessed by

Journal

Nuclear Medicine and Molecular Imaging – Springer Journals

Published: Jun 30, 2012

There are no references for this article.